Treatment of hairy cell leukemia with recombinant alpha 2 interferon

Ratain, Mark J.; Golomb, Harvey M.; Vardiman, James W.; Vokes, Everett E.; Jacobs, Renee H.; Daly, Karen

doi:10.1182/blood.v65.3.644.644

Cited by 127 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant clinical success of interferon therapy has been reported in the case of some B-cell neoplasms, notably hairy-cell leukaemia (Quesada ct d . , Ratain et al, 1985). but the mechanism o f the cessation of tumour growth is unclear.…”

mentioning

confidence: 99%

Anti‐proliferative effects of interferons on Daudiburkitt Lymphoma cells: Induction of cell differentiation and loss of response to autocrine growth factors

Exley

Gordon

Nathan

et al. 1987

Intl Journal of Cancer

View full text Add to dashboard Cite

Treatment of Daudi B-lymphoblastoid cells with low concentrations of either natural or recombinant human alpha-interferons inhibits cell proliferation and modulates the expression of a number of cell-surface antigens. Using a panel of monoclonal antibodies (MAbs) identifying determinants expressed at the surface of normal plasma cells, and polyclonal antibodies against surface and cytoplasmic immunoglobulin, we have found that growth inhibition is accompanied by plasmacytoid differentiation. Assays of growth stimulation of heterologous cells indicate that the culture medium from interferon-treated Daudi cells contains substantially more B-cell growth factor activity than that from control cells. However, the interferon-treated cells exhibit an impaired ability to respond to both these autocrine factors and exogenous factors produced by another Burkitt lymphoma line. These findings show that, in the case of Daudi cells, growth inhibition by interferons is closely associated with both terminal differentiation and a refractoriness to growth factors. In this system IFN-alpha may therefore be considered to be a B-cell differentiation factor, suggesting a possible basis for the anti-proliferative effects observed with certain human B-cell malignancies.

show abstract

mentioning

confidence: 99%

Anti‐proliferative effects of interferons on Daudiburkitt Lymphoma cells: Induction of cell differentiation and loss of response to autocrine growth factors

Exley

Gordon

Nathan

et al. 1987

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Although very 13 00 -11. 14 small doses were used in the current study, other investigators are seeking to determine whether the same antitumor effect can be achieved at an even lower dose, while minimizing toxicity.…”

Section: Discussionmentioning

confidence: 99%

Interferon in the treatment of hairy cell leukemia

Thompson¹,

Fefer²

1987

Cancer

View full text Add to dashboard Cite

An ongoing multicenter study has confirmed earlier observations that interferon alfa-2b (Intron A, Schering Corp., Kenilworth, NJ) is effective in the treatment of hairy cell leukemia (HCL). The 212 evaluable subjects in this trial received 2 X 10(6) U/m2 of interferon alfa-2b subcutaneously, on an outpatient basis, three times a week for 1 year. Of this group, 166 had previously undergone splenectomy, and 94 had received chemotherapy; 96% had more than 50% hairy cells in the bone marrow. Objective responses (complete, partial, and minor) were recorded in 89% of the study group and were characterized by a marked reduction in infections as well as in the need for transfusions. Complete response, defined as a normal complete blood count (CBC) and less than 5% hairy cells in the marrow, was achieved in 4% of the subjects. Partial responses (normal CBC) were attained in 74%, and minor responses (normalization of subnormal hematocrits or granulocyte or platelet counts) in 11%. Normalization of CBC usually did not occur until after 2 to 5 months of therapy. Results were comparable in splenectomized and nonsplenectomized patients. After 1 year of treatment, the responders were randomized to continue therapy for 6 months or to stop treatment and remain under observation. Preliminary findings have shown no significant differences in the incidence or time to progression of disease in the two groups, but additional data will be required before conclusions can be reached with regard to the need for maintenance therapy. Overall, the results of this study indicate that interferon alfa-2b is well tolerated, produces durable responses, and dramatically improves the quality of life in a high percentage of patients with progressive HCL.

show abstract

“…Recently, some reports (10)(11)(12)(13)(14) concerning the effectiveness of a-IFN against hairy cell leukemia (HCL) have been published. A very interesting idea is that human T-cell leukemia virus type I1 (HTLV-11) is the cause of HCL, as HTLV-I is the cause of ATL.…”

Section: Discussionmentioning

confidence: 99%

A first case of complete remission of β‐interferon sensitive adult T‐cell leukemia

Matsushima

Yoneyama

Nakamura

et al. 1987

European J of Haematology

View full text Add to dashboard Cite

A case of complete remission of adult T-cell leukemia (ATL) induced by p-interferon is reported. A 46-year-old male was diagnosed as ATL because of the increased number of ATL cells with deeply indented and lobulated nuclei in the peripheral blood, accompanied by elevated values of the lactic dehydrogenase, the alkaline phosphatase, and the calcium in the serum. The result of the cell surface marker analysis of peripheral blood lymphocytes was compatible with ATL and anti-ATL associated antibody (ATLA) was positive. The integration of proviral deoxyribonucleic acid (DNA) of human T-cell leukemia virus type I(HTLV-I) was proved in the peripheral blood lymphocytes using Southern blot hybridization. Since an ordinal chemotherapy was not so effective for this patient, he was treated with 1.8 x lo7 units of recombinant P-interferon (P-IFN) per day for 7 days as one course. After 5 courses of treatment, a markedly favorable response was recognized, and he achieved complete remission. A lower dose of P-IFN (9 x 106 units per day for 3 days as one course, one or two courses per month) has been continued and he has still been in a complete remission state for 10 months. It is concluded that P-IFN should be used to treat ATL.

show abstract

Treatment of hairy cell leukemia with recombinant alpha 2 interferon

Cited by 127 publications

References 11 publications

Anti‐proliferative effects of interferons on Daudiburkitt Lymphoma cells: Induction of cell differentiation and loss of response to autocrine growth factors

Anti‐proliferative effects of interferons on Daudiburkitt Lymphoma cells: Induction of cell differentiation and loss of response to autocrine growth factors

Interferon in the treatment of hairy cell leukemia

A first case of complete remission of β‐interferon sensitive adult T‐cell leukemia

Contact Info

Product

Resources

About